Colorectal cancer (CRC) remains one of the most formidable challenges in the global health arena. To address this challenge, extensive research has been directed toward developing targeted drug delivery systems (DDS). Cell-derived vesicles (CDV), which mirror the lipid bilayer structure of cell membranes, have garnered tremendous attention as ideal materials for DDS owing to their scalability in production and high biocompatibility. In this study, a novel method, termed colorectal cancer overall Dukes' staging Systematic Evolution of Ligands by Exponential enrichment (CROSS), was developed to identify Toggle Cell 1 (TC1) aptamers with high binding affinity to CRC cells at various Dukes' stages (A-D). Furthermore, a novel DDS was developed by incorporating a cholesterol-modified TC1 aptamer into CDV, which exhibited improved targeting ability and cellular uptake efficiency toward CRC cells compared to CDV alone. The results of this study highlight the potential efficacy of CDV in constructing a targeted DDS while overcoming the current challenges associated with other lipid-based DDS.

2023-04-11·Analytical chemistry

Efficient Labeling of Vesicles with Lipophilic Fluorescent Dyes via the Salt-Change Method.

Article

作者: Cha, Minkwon ; Park, Jun Hyuk ; Kim, Sang Soo ; Shon, Min Ju ; Gho, Yong Song ; Bae, Seoyoon ; Park, Jeong Eun ; Han, Dong Woo ; Shin, Jaehyeon ; Jeong, Sang Hyeok ; Baeg, Yoonjin ; Oh, Seung Wook

Fluorescent labeling allows for imaging and tracking of vesicles down to single-particle level. Among several options to introduce fluorescence, staining of lipid membranes with lipophilic dyes provides a straightforward approach without interfering with vesicle content. However, incorporating lipophilic molecules into vesicle membranes in an aqueous solution is generally not efficient because of their low water solubility. Here, we describe a simple, fast (<30 min), and highly effective procedure for fluorescent labeling of vesicles including natural extracellular vesicles. By adjusting the ionic strength of the staining buffer with NaCl, the aggregation status of DiI, a representative lipophilic tracer, can be controlled reversibly. Using cell-derived vesicles as a model system, we show that dispersion of DiI under low-salt condition improved its incorporation into vesicles by a factor of 290. In addition, increasing NaCl concentration after labeling induced free dye molecules to form aggregates, which can be filtered and thus effectively removed without ultracentrifugation. We consistently observed 6- to 85-fold increases in the labeled vesicle count across different types of dyes and vesicles. The method is expected to reduce the concern about off-target labeling resulting from the use of high concentrations of dyes.

2022-12-01·Regenerative Therapy

Cell-derived vesicles from adipose-derived mesenchymal stem cells ameliorate irradiation-induced salivary gland cell damage

Article

作者: Choi, Mi Eun ; Choi, Jeong-Seok ; Kim, Jeong Mi ; Oh, Seung Wook ; Park, Jin-Mi ; Kim, Sungryeal ; Park, Jeong Eun ; Jeon, Eun Jeong

IntroductionSalivary gland (SG) damage is commonly caused by aging, irradiation, and some medications, and currently, no damage modifying agent is available. However, cell therapy based on mesenchymal stem cells (MSCs) has been proposed as a therapeutic modality for irradiated SGs. Therefore, we administered cell-derived vesicles (CDVs) of adipose-derived mesenchymal stem cells (ADMSCs) to irradiated SG cells to investigate their radioprotective effects in vitro.MethodsThe artificial CDVs were obtained from ADMSC by tangential flow filtration (TFF) purification and ultracentrifugation. Cultured human SG epithelial cells were exposed to 2, 5 or 15 Gy of 4 MV X-rays produced by a linear accelerator. The effects of ADMSC-CDVs on SG epithelial cells damaged by irradiation were tested by proliferation activity, transepithelial electrical resistance (TEER), and amylase activity.ResultsExposure to penetrating radiation inhibited the proliferation of SG epithelial cells, but the radiation intensity required to reduce the proliferation of human submandibular gland epithelial cells (hSMGECs) was greater than required for other SG cells. ADMSC-CDVs restored the proliferative ability of SG epithelial cells reduced by irradiation, and the proliferation capacities of irradiated human parotid gland epithelial cells (hPGECs) and human sublingual gland epithelial cells (hSLGECs) were increased by administering ADMSC-CDVs to non-irradiated SG epithelial cells. Furthermore, amylase activity in irradiated hPGECs, hSMGECs, and hSLGECs was lower than in non-irradiated controls. However, amylase ability was restored in all by ADMSC-CDV treatment. Also, TEER was diminished by irradiation in hPGECs, hSMGECs, and hSLGECs and restored by ADMSC-CDV administration.ConclusionOverall, our findings demonstrate that ADMSC-CDVs have potent radioprotective effects on irradiated SG cells.

项与 MDimune, Inc. 相关的新闻（医药）

2023-10-05

·BioSpace

MDimune Inc. broadens its global footprint with residency at JLABS @ Shanghai

Seoul, Korea, October 05, 2023 – MDimune Inc. announced today that it took up residence at Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’), located in Shanghai, China, starting in September. A representative from MDimune stated, “We have been exploring ways to effectively introduce the technical prowess of our next-generation drug delivery system, the Bio Drone™ platform, to global companies and to expand our investment network.” By joining JLABS MDimune intends to access the global network of Johnson & Johnson Innovation with the objective of engaging in research collaborations and technology transfers with global innovative companies. Moreover, MDimune is looking to benefit from the support of experts within the Johnson & Johnson Innovation, R&D and commercial teams, entrepreneurial programs, and other benefits of residency, including access to potential investment opportunities. MDimune's CEO, Shingyu Bae, stated, "Joining JLABS provides an opportunity to expand our network with globally renowned experts and research institutions." He added, "Utilizing JLABS' resources and network will be a crucial turning point in developing innovative ideas and growing our company." About MDimune Inc. MDimune Inc., founded in 2015, is a biotech company headquartered in Seoul, Korea, and has been dedicated to the development of the innovative therapeutic platform BioDrone™. The novel BioDrone™ platform technology uses cell-derived vesicles to overcome the limitations of existing cell therapies or achieve target-specific drug delivery. BioDrone™ platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune is actively pursuing business partnerships with biotech and pharmaceutical companies for the potential application of the BioDrone™ technology for various unmet medical needs. For more information, please visit the company's websites, or , or watch the BioDrone™ Platform Technology video on . For more information, please visit Media Contact Spokesperson: Jisun Lee Company Website: Email: ljs@mdimune.com Phone: +82-2-2655-2636

细胞疗法

2023-04-24

·Business Wire

MDimune Wins Bronze at 2023 Edison Awards

SEOUL, South Korea--( BUSINESS WIRE )-- MDimune Inc. , a Korean biotech company developing BioDrone™ platform technology, has won the Bronze Award at the 2023 Edison Awards . The company has won in the Health, Medical & Biotech category for its next-generation drug delivery platform BioDrone™, along with US-based biotech Moderna (Gold) and the Taiwanese research organization Industrial Technology Research Institute (ITRI) (Silver). The Edison Awards, also known as the "Oscars of Innovation," are named after the inventor Thomas Edison and recognize the highest levels of innovation, creativity, and ingenuity in technology, products, and business literature that demonstrate the greatest potential for positive impact in various industry sectors. Over 3,000 judges representing each industry sector evaluate entries for approximately seven months before selecting the winners. MDimune’s BioDrone™ technology addresses the most critical limitations of the current drug delivery systems, such as a wide range of side effects and limited targeting abilities. Derived from natural human cells, cell-derived vesicles (CDVs) produced by extrusion technology display little toxicity or immunogenicity while exhibiting a high level of flexibility to allow various surface engineering, which can be used to steer vesicles toward lesions in a more selective manner. Compared to similar classes of nanovesicles like exosomes, the company’s proprietary extrusion technology enables up to 100 times greater yield in vesicle production that is more suitable for clinical applications. MDimune has been acknowledged for the outstanding quality and innovativeness of its BioDrone platform at the 2023 Edison Awards. MDimune's BioDrone™ platform can be accessed for viewing on both the company's official website and the Edison Awards website . About MDimune Inc. Biotech company headquartered in Seoul, South Korea, that specializes in the development of BioDrone™ platform, innovative therapeutic based on cell-derived vesicles (CDV). BioDrone™ Platform Technology video: https://youtu.be/lwwDQOpyKs4 . About The Edison Awards Established in 1987, the Edison Awards is a program conducted by Edison Universe, a non-profit 501(c)(3) organization dedicated to fostering future innovators. The annual competition honors excellence in new product and service development, marketing, design and innovation. Past award recipients include Steve Jobs, Elon Musk, and leaders of global corporations such as Coca-Cola, Genentech, General Electric, General Motors, IBM and Campbell Soup Co. In 2022, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit www.edisonawards.com .

2023-02-22

·BioSpace

MDimune Named as a Finalist in the Prestigious 2023 Edison Awards™

BioDroneTM next-generation drug delivery platform honored for excellence alongside other innovators and innovations in the Health, Medical & Biotech category MDimune Inc., a Korean biotech company developing BioDroneTM platform technology, has been named a finalist in the 2023 Edison Awards. The company is being honored in the Health, Medical & Biotech category for its next-generation drug delivery platform BioDroneTM based on cell-derived vesicles (CDVs). MDimune’s BioDroneTM technology addresses the most critical limitations of the current drug delivery systems, such as a wide range of side effects and limited targeting abilities. Derived from natural human cells, CDVs produced by extrusion technology display little toxicity or immunogenicity while exhibiting a high level of flexibility to allow various surface engineering, which can be used to steer vesicles toward lesions in a more selective manner. Compared to similar classes of nanovesicles like exosomes, the company’s proprietary extrusion technology enables up to 100 times greater yield in vesicle production that is more suitable for clinical applications. The Edison Awards™, named after the American inventor Thomas Alva Edison, recognizes some of the most innovative products and business leaders in the world with past winners including Steve Jobs, Elon Musk, General Motors and Genentech. The prestigious accolades honor excellence in new product and service development, marketing, design and innovation. All nominations are reviewed by the Edison Awards Steering Committee with the final ballot being determined by an independent judging panel. The panel is comprised of more than 3,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners. MDimune was included in three finalists in the Advanced Drug Delivery subcategory along with US-based biotech Moderna and the Taiwanese research organization Industrial Technology Research Institute (ITRI). Gold, Silver and Bronze winners will be announced at the Edison Awards Gala on Thursday, April 20, 2023, in Fort Myers, FL. Mr. Shingyu Bae, CEO of MDimune said, “We are delighted that BioDrone’s technological prowess and innovation were recognized at the world-renowned Edison Awards. Through this award, we wish to expand the opportunities to connect with and possibly license our platform technology to more global partners.” About MDimune MDimune Inc., founded in 2015, is a biotech company headquartered in Seoul, Korea, and has been dedicated to the development of the innovative therapeutic platform BioDrone™. The novel BioDrone™ platform technology uses cell-derived vesicles to overcome the limitations of existing cell therapies or achieve target-specific drug delivery. BioDrone™ platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune is actively pursuing business partnerships with biotech and pharmaceutical companies for the potential application of the BioDrone™ technology for various unmet medical needs. For more information, please visit the company's websites, or , or watch the BioDrone™ Platform Technology video on . About The Edison Awards Established in 1987, the Edison Awards is a program conducted by Edison Universe, a non-profit 501(c)(3) organization dedicated to fostering future innovators. The annual competition honors excellence in new product and service development, marketing, design and innovation. Past award recipients include Steve Jobs, Elon Musk, and leaders of global corporations such as Coca-Cola, Genentech, General Electric, General Motors, IBM and Campbell Soup Co. In 2022, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit . BioDrone™ Platform Technology video: Contact: Jisun Lee, Manager, Communications / +82 70-7826-2623/ ljs@mdimune.com

细胞疗法

100 项与 MDimune, Inc. 相关的药物交易

登录后查看更多信息

100 项与 MDimune, Inc. 相关的转化医学

登录后查看更多信息